The company also has data showing that Adva-27a can kill other aggressive and multidrug-resistant cells including breast cancer, small-cell lung cancer and uterine sarcoma

The company also has data showing that Adva-27a can kill other aggressive and multidrug-resistant cells including breast cancer, small-cell lung cancer and uterine sarcoma

Pursuant to the agreement, the company may from time to time sell up to a maximum of $20 million of the company's American Depositary Shares (ADSs

The FDA approved Tarceva (erlotinib) tablets for first-line treatment of metastatic non-small-cell lung cancer characterized by tumors with epidermal growth factor receptor-activating mutations

CytRx Corp., of Los Angeles, said an independent data safety monitoring committee (DSMC) recommended the company discontinue its Phase IIb trial with tamibarotene as first-line treatment in advanced non-small-cell lung cancer

GTx Inc., of Memphis, Tenn., said that an independent data safety monitoring board determined that it should continue as planned two pivotal Phase III trials of enobosarm (GTX-024) for muscle wasting in patients with advanced non-small cell lung cancer

Axelar AB, of Stockholm, Sweden, part of the Karolinska Development AB portfolio, reported preliminary interim results from its Phase II study of AXL1717, indicating that the small-molecule IGF-1 receptor inhibitor is effective in treating patients with non-small-cell lung cancer

Sorrento Therapeutics Inc., of San Diego, signed an exclusive option to acquire Igdrasol Inc., of Fountain Valley, Calif., a private company focused on the development of oncologic agents for the treatment of metastatic breast cancer (MBC), non-small-cell lung cancer (NSCLC) and other cancers

Synta Pharmaceuticals Corp., of Lexington, Mass., selected contract research organization PSI CRO, of Zug, Switzerland, to carry out its GALAXY-2 Phase III trial of ganetespib with docetaxel in non-small-cell lung cancer

Sunshine Biopharma Inc., of Montreal, said it completed seven in vitro studies, in which Adva-27a showed potent antitumor activity in every cell line tested, including multidrug-resistant breast cancer, multidrug-resistant uterine cancer and small-cell lung cancer

At all doses tested, ALX-0061 was well tolerated and the safety profile compared favorably to data reported for other biological DMARDs...To date, almost 50 percent of planned patients have been enrolled in about 30 European centers...In both studies the JE vaccine was shown to be highly immunogenic in children/adolescents age 2 months to younger than 18 years with a safety profile comparable to pediatric vaccines licensed for other diseases

OSE Pharma SA, of Paris, said the FDA granted orphan drug status to its lead candidate, OSE 2101, to treat non-small-cell lung cancer (NSCLC) in patients expressing HLA-A2

OxOnc Development LP, of Princeton, N.J., said it entered a co-development agreement with Pfizer Inc., of New York, to conduct a pivotal trial of Pfizer's Xalkori (crizotinib) in patients with non-small-cell lung cancer harboring a ROS1 (c-ros) gene rearrangement

The FDA approved Abraxane (paclitaxel protien-bound particles), by Celgene Corp., of Summit, N.J., in combination with carboplatin for first-line treatment of locally advanced or metastatic non-small-cell lung cancer in patients who are not candidates for surgery or radiation

The compound also is in a Phase II study in non-small-cell lung cancer

Astellas Pharma Inc., of Tokyo, said the FDA accepted for filing a supplemental new drug application for Tarceva (erlotinib) for first-line use in patients with locally advanced or metastatic non-small-cell lung cancer whose tumors have epidermal growth factor receptor (EGFR)-activating mutations...Afatinib is under review for the treatment of patients with locally advanced or metastatic non-small-cell lung cancer with an epidermal growth factor receptor mutation as detected by an FDA-approved test

In preclinical xenograft studies using patient-derived breast cancer and non-small-cell lung cancer material, Synthon reported complete tumor remission

Astellas Pharma Inc., of Tokyo, said the FDA accepted for filing a supplemental new drug application for Tarceva (erlotinib) for first-line use in patients with locally advanced or metastatic non-small-cell lung cancer whose tumors have epidermal growth factor receptor (EGFR)-activating mutations

Afatinib is under review for the treatment of patients with locally advanced or metastatic non-small-cell lung cancer with an epidermal growth factor receptor mutation as detected by an FDA-approved test